Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C Kramer
Bevacizumab Reduces VEGF Expression in Patients With Relapsed and Refractory Acute Myeloid Leukemia Without Clinical Antileukemic Activity
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Clinical Experience With the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies
American Journal of Hematology
Hematology
Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
Clinical Hematology International
Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
Leukemia Research
Cancer Research
Oncology
Hematology
Comparison of Clinical Remission and Survival Between CLAG and FLAG Induction Chemotherapy in Patients With Refractory or Relapsed Acute Myeloid Leukemia: A Prospective Cohort Study
Clinical and Translational Oncology
Medicine
Cancer Research
Oncology
The mTOR Inhibitor Everolimus in Combination With Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase Ib/Ii Study
Oncotarget
Oncology
A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients With Relapsed/Refractory Acute Myeloid Leukemia
Advances in Hematology
Hematology
